…nalyze the data on the drug. Some doctors argued its use should be restricted mainly to patients with FH. But Mark Schoenebaum, Evercore ISI's pharmaceutical analyst, says that investors were initially disappointed because they had hoped th...
Fwd: FDA Approved a Potent and Pricey Cholesterol lowering drug today
TEXT-001-HOUSE_OVERSIGHT_025888.txt
p.1
View source release ↗